The complainant requested an executable version of the economic model used by NICE in its assessment of Donepezil, Rivastigmine, Galantamine and Memantine, drugs that are used to treat Alzheimer’s Disease. NICE refused to provide the information citing the exemptions in sections 36 and 41 of the Act. The Commissioner has decided that NICE appropriately relied upon section 41 when refusing to supply the information. He has also found that NICE breached section 10 of the Act in initially failing to respond to the request within twenty working days. The Commissioner has not ordered any remedial steps. This decision notice is currently under appeal to the information tribunal.
FOI 10: Upheld
Citations:
[2007] UKICO FS50082569
Links:
Jurisdiction:
England and Wales
Information
Updated: 25 April 2022; Ref: scu.533072